2Johnstone D, Berger C, Fleckman P, et al. Acute ful minant hepattis after treatment with rabeprazole and tebinafine[J]. Arch Intern MM .2001.161 : 1677.
4Tytgat GNJ. Shortcomings of the first-generation proton pump inhibitors[J]. Eur J Gastroenterol Hapatol, 2001,13 (Suppl 1):29.
5Sachs G, Shin JM. The Pharmacology of the gastric acid pump.The H^+ , K^+ ATPase[J]. Annu Rev Phamacol Toxicol, 1995,35 : 277.
6Besancon M,Simon A,Sachs G, et al. Sites of reaction of the gastric H^+ , K ^+ ATPase with extraytoplasmic thiol regents[ J ]. J Biol Chen, 1997,272 : 22438.
7Carswell CI ,Goa KL. Rabeprazole. an update of its use in acid-related disorders[J]. Drugs ,2001,61:2327.
8LangtryHD,Markham A. Rabeprazole:a review of its use in acidrelated gastrointestinal disorders[J]. Drugs, 1999,58 : 725.
9Prakash A, Faulds D. Rabeprazole[ J ]. Drugs, 1998,55 : 261.
10Kawakami Y,Akahane T,Yamaguchi M, et al. In vitro activities of rabeprazole, a novel proton pump inhibitor and its thioether derivative alone and combination with other antimicobials agains trecent clinical isolates of Helicobacter pylori[J]. Antimicrob Agent Chemother, 2000,44: 458.
9Vakil N, van Zanten SV, Kahrilas P, et al. The Montreal definition and classification of gastreesophageal reflux disease: A global evidence based consensu. Am J Gastreentere1,2006,101 : 1900-1920.
10Irvine E J, Whitehead WE, Chey WD, et al. Design of treatment trials for functional gastrointestinal, disorders. Gastroenterology, 2006, 130 : 538- 551.
